ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$16.59 USD
-0.15 (-0.90%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $16.57 -0.02 (-0.12%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum B VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ACAD 16.59 -0.15(-0.90%)
Will ACAD be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ACAD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACAD
Why Is Acadia (ACAD) Down 23.4% Since Last Earnings Report?
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
ACAD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails
Acadia (ACAD) Q4 Earnings Lag, Sales Beat Estimates, Stock Down
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates
Other News for ACAD
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
Acadia Pharmaceuticals announces Health Canada acceptance of trofinetide NDS
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting